600812 Stock Overview
North China Pharmaceutical Company.Ltd operates as a chemical pharmaceutical company in China.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
North China Pharmaceutical Company.Ltd Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥4.91 |
52 Week High | CN¥6.66 |
52 Week Low | CN¥3.83 |
Beta | 0.83 |
1 Month Change | 6.05% |
3 Month Change | -0.61% |
1 Year Change | -21.82% |
3 Year Change | -51.96% |
5 Year Change | 3.37% |
Change since IPO | 182.90% |
Recent News & Updates
Shareholder Returns
600812 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | 9.8% | 4.9% | 2.1% |
1Y | -21.8% | -13.4% | -14.2% |
Return vs Industry: 600812 underperformed the CN Pharmaceuticals industry which returned -14.4% over the past year.
Return vs Market: 600812 underperformed the CN Market which returned -14.6% over the past year.
Price Volatility
600812 volatility | |
---|---|
600812 Average Weekly Movement | 5.7% |
Pharmaceuticals Industry Average Movement | 7.6% |
Market Average Movement | 8.7% |
10% most volatile stocks in CN Market | 12.7% |
10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 600812 has not had significant price volatility in the past 3 months.
Volatility Over Time: 600812's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1953 | 10,159 | Xin Yan Liu | www.ncpc.com |
North China Pharmaceutical Company Ltd operates as a chemical pharmaceutical company in China. It primarily offers anti-infective drugs; biotechnology drugs; cardiovascular cerebrovascular; immunomodulators; vitamins health consumer products; and bio-agricultural and veterinary drugs.
North China Pharmaceutical Company.Ltd Fundamentals Summary
600812 fundamental statistics | |
---|---|
Market cap | CN¥8.42b |
Earnings (TTM) | CN¥17.62m |
Revenue (TTM) | CN¥10.02b |
478.0x
P/E Ratio0.8x
P/S RatioIs 600812 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
600812 income statement (TTM) | |
---|---|
Revenue | CN¥10.02b |
Cost of Revenue | CN¥6.91b |
Gross Profit | CN¥3.11b |
Other Expenses | CN¥3.09b |
Earnings | CN¥17.62m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.01 |
Gross Margin | 31.02% |
Net Profit Margin | 0.18% |
Debt/Equity Ratio | 170.2% |
How did 600812 perform over the long term?
See historical performance and comparison